Boston Scientific’s Watchman implant cut bleeding risks almost in half compared to long-term anticoagulant regimens, while showing it was non-inferior in composite measures of stroke and death in people with atrial fibrillation.
- Home |
- Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial
Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial
- March 30, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
